article thumbnail

Novo Nordisk to buy Emisphere and diabetes pill tech for $1.8bn

pharmaphorum

billion, as it continues its quest to develop diabetes medicines that can be taken as pills. The two companies have been working together since 2007 and Emisphere’s technology is already used under a licence agreement in the formulation for Rybelsus. Novo Nordisk has agreed to buy Emisphere Technologies for $1.8

Diabetes 111
article thumbnail

Why the drug pricing debate is focused on insulin

pharmaphorum

It has now been 100 years since the first patient with diabetes received an injection of insulin, when Leonard Thomas, a 14-year-old boy, was treated with the hormone. In recent years, there have been more developments in the area of diabetes management, with the emergence of metformin and more recently semaglutide and dulaglutide.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

SAEM Clinical Images Series: Insidiously Contracted Hand

ALiEM - Pharm Pearls

Risk factors for the development of Dupuytren’s contracture include northern European descent, age greater than 50 years, and diabetes. Repetitive motion occupations, tobacco use, alcohol use, and diabetes are key risk factors. Am Fam Physician 2007; 76:86. Case Question: What are the risk factors for this condition?

Diabetes 152
article thumbnail

Sensyne launches fundraising, agrees patient data deal with Phesi

pharmaphorum

Oxford-based Sensyne uses patient data to improve drug development, disease understanding and clinical trial design, as well as to discover new drug targets, and also develops digital health software applications powered by AI such as GDm-Health for diabetes and CVm-Health for COVID-19. It already has access to around 6.1

article thumbnail

EU Committee Recommends Approval of 6 New Biosimilars in July 2024 Meeting

Big Molecule Watch

Midas Pharma GmbH’s Ranibizumab Midas for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular oedema, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization.

article thumbnail

Why Balancing Blood Sugar is Vital for Hashimoto’s Health

The Thyroid Pharmacist

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

article thumbnail

Developing a holistic approach to cardio, metabolic and renal disease

European Pharmaceutical Review

“Empagliflozin is an oral, once daily, highly selective sodium-glucose cotransporter 2 or SGLT2 inhibitor… It was originally developed for type 2 diabetes because it improves glycaemic control,” explained Dr Clark. of type 2 diabetes patients overall and was the cause of death for 10 percent of type 2 diabetes patients.